Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors (ELUCIDATE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05985655 |
Recruitment Status :
Recruiting
First Posted : August 14, 2023
Last Update Posted : March 5, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Advanced Solid Tumor | Drug: GTAEXS617 | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 170 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors |
Actual Study Start Date : | July 6, 2023 |
Estimated Primary Completion Date : | January 2028 |
Estimated Study Completion Date : | May 2028 |
Arm | Intervention/treatment |
---|---|
Experimental: GTAEXS617
GTAEXS617 tablet for oral administration
|
Drug: GTAEXS617
GTAEXS617 tablets daily |
- Module 1 Part A: To characterize the safety profile of GTAEXS617 as monotherapy [ Time Frame: Through patient study completion, an average of 6 months ]Incidence of treatment-emergent adverse events (TEAEs), characterised by type, incidence, severity (graded by NCI CTCAE v5.0), seriousness, timing and relationship to GTAEXS617 dosing.
- Module 1 Part A: To characterize the Dose Limiting Toxicities (DLTs) of GTAEXS617 as monotherapy [ Time Frame: Through patient study completion, an average of 6 months ]Incidence of dose limiting toxicities (DLTs) during Cycle 1 of treatment.
- Module 1 Part A: To establish the Recommended Phase 2 Dose (RP2D) of GTAEXS617 as monotherapy [ Time Frame: Through study completion for all patients in Module 1 Part A. Estimated 18 months. ]The RP2D will not exceed the maximum tolerated dose (MTD) if established.
- Module 1 Part B: To characterize the safety profile of GTAEXS617 in combination with selected Standard of Care (SoC) regimens [ Time Frame: Through patient study completion, an average of 6 months ]Incidence of treatment-emergent adverse events (TEAEs), characterised by type, incidence, severity (graded by NCI CTCAE v5.0), seriousness, timing and relationship to GTAEXS617 dosing.
- Module 1 Part B: To characterize the Dose Limiting Toxicities (DLTs) of GTAEXS617 in combination with selected Standard of Care (SoC) regimens [ Time Frame: Through patient study completion, an average of 6 months ]Incidence of dose limiting toxicities (DLTs) during Cycle 1 of treatment
- Module 1 Part A: GTAEXS617 Maximum Plasma Concentration (Cmax) [ Time Frame: Through patient study completion, an average of 6 months ]Maximum Plasma Concentration (Cmax) when GTAEXS617 administered as monotherapy
- Module 1 Part A: GTAEXS617 Time Maximum Plasma Concentration (Tmax) [ Time Frame: Through patient study completion, an average of 6 months ]Time Maximum Plasma Concentration (Tmax) when GTAEXS617 administered as monotherapy
- Module 1 Part A: GTAEXS617 Area under Plasma Concentration Curve during 24 hour dosing interval (AUC 0-tau) [ Time Frame: Through patient study completion, an average of 6 months ]Area under Plasma Concentration Curve during 24 hour dosing interval (AUC 0-tau) when GTAEXS617 administered as monotherapy
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- ECOG performance status 0-1
- Life expectancy >3 months
- One the following histologically or cytologically confirmed advanced solid tumors: head and neck squamous cell carcinoma, colorectal adenocarcinoma, pancreatic adenocarcinoma, NSCLC, breast carcinoma (HR+ and HER2- that has progressed to a prior treatment with CD4/CDK6 inhibitor), or ovarian epithelial carcinoma
- Patients must have disease that is advanced (ie, surgery or radiotherapy are not considered to be potentially curative), recurrent, or metastatic following SoC treatments
- Adequate hematological, liver, and renal function
- Participant must have tumor lesion(s) or metastases amenable to biopsy, excluding bone metastases
Exclusion Criteria:
- Active and clinically significant (CS) infection
- Refractory nausea and/or vomiting, chronic gastrointestinal disease, or previous significant bowel resection, with CS sequelae that would preclude adequate absorption of GTAEXS617
- Symptomatic central nervous system (CNS) malignancy or metastases
- Concurrent active or previous malignancy
- Prior organ or allogeneic stem-cell transplantation
- Moderate or severe cardiovascular disease
- Received anticancer therapy within 28 days or 5 half-lives (whichever is shorter) before the first dose of the study treatment
- Received treatment with known strong inhibitors and or inducers of cytochrome P450 3A isoform subfamily (CYP3A) within 14 days or 5 half-lives before the first dose of study treatment
- Received treatment with known inhibitors or inducers of P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) within 14 days or 5 half-lives before the first dose of study
- Received treatment with known substrates of organic anion transporting peptide 1B3 (OATP1B3) or BCRP within 14 days or 5 half-lives before the first dose of study treatment
- Unresolved or unstable serious toxic side-effects of prior chemotherapy or radiotherapy
- Has had or is scheduled to have major surgery <28 days prior to the first dose of study treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05985655
Contact: Holly Garratt | +441865 818941 | info@exscientia.co.uk | |
Contact: Eric Helmer | +441865 818941 | info@exscientia.co.uk |
Belgium | |
Clinique Universitaires Saint-Luc | Recruiting |
Brussels, Belgium | |
Principal Investigator: Rachel Galot | |
CHU Sart Tilman | Recruiting |
Liège, Belgium | |
Principal Investigator: Laurence Lousberg | |
United Kingdom | |
The Beatson West of Scotland Cancer Centre | Recruiting |
Glasgow, United Kingdom | |
Principal Investigator: Jeff Evans | |
UCL Hospitals NHS Foundation Trust | Recruiting |
London, United Kingdom | |
Principal Investigator: Martin Forster | |
The Christie NHS Foundation Trust | Recruiting |
Manchester, United Kingdom | |
Principal Investigator: Donna Graham | |
Newcastle Upon Tyne NHS Foundation Trust | Recruiting |
Newcastle Upon Tyne, United Kingdom | |
Principal Investigator: Elizabeth Ruth Plummer | |
Oxford University Hospitals NHS Foundation Trust | Recruiting |
Oxford, United Kingdom | |
Principal Investigator: Simon Lord |
Responsible Party: | Exscientia AI Limited |
ClinicalTrials.gov Identifier: | NCT05985655 |
Other Study ID Numbers: |
GTAEXS617-001 |
First Posted: | August 14, 2023 Key Record Dates |
Last Update Posted: | March 5, 2024 |
Last Verified: | March 2024 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Neoplasms |